These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11115721)

  • 1. CpG DNA is an effective oral adjuvant to protein antigens in mice.
    McCluskie MJ; Weeratna RD; Krieg AM; Davis HL
    Vaccine; 2000 Nov; 19(7-8):950-7. PubMed ID: 11115721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
    McCluskie MJ; Weeratna RD; Davis HL
    Vaccine; 2001 Mar; 19(17-19):2657-60. PubMed ID: 11257405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.
    McCluskie MJ; Davis HL
    Vaccine; 2000 Oct; 19(4-5):413-22. PubMed ID: 11027803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
    J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    FEMS Immunol Med Microbiol; 2002 Feb; 32(3):179-85. PubMed ID: 11934561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
    McCluskie MJ; Weeratna RD; Davis HL
    Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
    Diwan M; Tafaghodi M; Samuel J
    J Control Release; 2002 Dec; 85(1-3):247-62. PubMed ID: 12480329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ; Davis HL
    J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
    Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
    J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
    McCluskie MJ; Weeratna RD; Clements JD; Davis HL
    Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12.
    Schirmbeck R; Reimann J
    Intervirology; 2001; 44(2-3):115-23. PubMed ID: 11509872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid.
    Eastcott JW; Holmberg CJ; Dewhirst FE; Esch TR; Smith DJ; Taubman MA
    Vaccine; 2001 Feb; 19(13-14):1636-42. PubMed ID: 11166886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG DNA as mucosal adjuvant.
    McCluskie MJ; Davis HL
    Vaccine; 1999 Sep; 18(3-4):231-7. PubMed ID: 10506647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
    Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
    FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine.
    Kojima Y; Xin KQ; Ooki T; Hamajima K; Oikawa T; Shinoda K; Ozaki T; Hoshino Y; Jounai N; Nakazawa M; Klinman D; Okuda K
    Vaccine; 2002 Jul; 20(23-24):2857-65. PubMed ID: 12126895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites.
    Horner AA; Datta SK; Takabayashi K; Belyakov IM; Hayashi T; Cinman N; Nguyen MD; Van Uden JH; Berzofsky JA; Richman DD; Raz E
    J Immunol; 2001 Aug; 167(3):1584-91. PubMed ID: 11466380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens.
    Kovarik J; Bozzotti P; Tougne C; Davis HL; Lambert PH; Krieg AM; Siegrist CA
    Immunology; 2001 Jan; 102(1):67-76. PubMed ID: 11168639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming.
    Kovarik J; Bozzotti P; Love-Homan L; Pihlgren M; Davis HL; Lambert PH; Krieg AM; Siegrist CA
    J Immunol; 1999 Feb; 162(3):1611-7. PubMed ID: 9973420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.